{"pmid":32371150,"title":"Immediate impact of COVID-19 on transplant activity in the Netherlands.","text":["Immediate impact of COVID-19 on transplant activity in the Netherlands.","The rapid emergence of the COVID-19 pandemic is unprecedented and poses an unparalleled obstacle in the sixty-five year history of organ transplantation. Worldwide, the delivery of transplant care is severely challenged by matters concerning - but not limited to - organ procurement, risk of SARS-CoV-2 transmission, screening strategies of donors and recipients, decisions to postpone or proceed with transplantation, the attributable risk of immunosuppression for COVID-19 and entrenched health care resources and capacity. The transplant community is faced with choosing a lesser of two evils: initiating immunosuppression and potentially accepting detrimental outcome when transplant recipients develop COVID-19 versus postponing transplantation and accepting associated waitlist mortality. Notably, prioritization of health care services for COVID-19 care raises concerns about allocation of resources to deliver care for transplant patients who might otherwise have excellent 1-year and 10-year survival rates. Children and young adults with end-stage organ disease in particular seem more disadvantaged by withholding transplantation because of capacity issues than from medical consequences of SARS-CoV-2. This report details the nationwide response of the Dutch transplant community to these issues and the immediate consequences for transplant activity. Worrisome, there was a significant decrease in organ donation numbers affecting all organ transplant services. In addition, there was a detrimental effect on transplantation numbers in children with end-organ failure. Ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs.","Transpl Immunol","de Vries, A P J","Alwayn, I P J","Hoek, R A S","van den Berg, A P","Ultee, F C W","Vogelaar, S M","Haase-Kromwijk, B J J M","Heemskerk, M B A","Hemke, A C","Nijboer, W N","Schaefer, B S","Kuiper, M A","de Jonge, J","van der Kaaij, N P","Reinders, M E J","32371150"],"abstract":["The rapid emergence of the COVID-19 pandemic is unprecedented and poses an unparalleled obstacle in the sixty-five year history of organ transplantation. Worldwide, the delivery of transplant care is severely challenged by matters concerning - but not limited to - organ procurement, risk of SARS-CoV-2 transmission, screening strategies of donors and recipients, decisions to postpone or proceed with transplantation, the attributable risk of immunosuppression for COVID-19 and entrenched health care resources and capacity. The transplant community is faced with choosing a lesser of two evils: initiating immunosuppression and potentially accepting detrimental outcome when transplant recipients develop COVID-19 versus postponing transplantation and accepting associated waitlist mortality. Notably, prioritization of health care services for COVID-19 care raises concerns about allocation of resources to deliver care for transplant patients who might otherwise have excellent 1-year and 10-year survival rates. Children and young adults with end-stage organ disease in particular seem more disadvantaged by withholding transplantation because of capacity issues than from medical consequences of SARS-CoV-2. This report details the nationwide response of the Dutch transplant community to these issues and the immediate consequences for transplant activity. Worrisome, there was a significant decrease in organ donation numbers affecting all organ transplant services. In addition, there was a detrimental effect on transplantation numbers in children with end-organ failure. Ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs."],"journal":"Transpl Immunol","authors":["de Vries, A P J","Alwayn, I P J","Hoek, R A S","van den Berg, A P","Ultee, F C W","Vogelaar, S M","Haase-Kromwijk, B J J M","Heemskerk, M B A","Hemke, A C","Nijboer, W N","Schaefer, B S","Kuiper, M A","de Jonge, J","van der Kaaij, N P","Reinders, M E J"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371150","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.trim.2020.101304","keywords":["covid-19","outbreak","sars-cov-2","transplant programs","transplantation"],"locations":["Dutch","Netherlands"],"countries":["Netherlands"],"countries_codes":["NLD|Netherlands"],"topics":["Prevention"],"weight":1,"_version_":1666138496449904640,"score":9.490897,"similar":[{"pmid":32348042,"title":"[SARS-CoV-2 infection and solid organ transplantation].","text":["[SARS-CoV-2 infection and solid organ transplantation].","Transplantation has become a valid therapeutic option for an increasing number of patients with end-stage organ disease. The emergence of SARS-CoV-2 coronavirus infection and associated disease (COVID-19) has alarmed the transplant community, since recommendations for adequate follow-up of organ transplant recipients during the acute phase of a pandemic are limited. Furthermore, treatment options against COVID-19 disease and adequate adjustment of immunosuppression in at risk patients remain a concern. This review summarizes current knowledge on the incidence and clinical course of SARS-CoV-2 infection in patients with solid organ transplantation. It also discusses therapeutic strategies and provides general recommendations on how to proceed with transplantation programs in a time when health care resources may become scarce.","Rev Med Suisse","Golshayan, Dela","Aubert, John-David","Hullin, Roger","Moradpour, Darius","Venetz, Jean-Pierre","Manuel, Oriol","Pascual, Manuel","32348042"],"abstract":["Transplantation has become a valid therapeutic option for an increasing number of patients with end-stage organ disease. The emergence of SARS-CoV-2 coronavirus infection and associated disease (COVID-19) has alarmed the transplant community, since recommendations for adequate follow-up of organ transplant recipients during the acute phase of a pandemic are limited. Furthermore, treatment options against COVID-19 disease and adequate adjustment of immunosuppression in at risk patients remain a concern. This review summarizes current knowledge on the incidence and clinical course of SARS-CoV-2 infection in patients with solid organ transplantation. It also discusses therapeutic strategies and provides general recommendations on how to proceed with transplantation programs in a time when health care resources may become scarce."],"journal":"Rev Med Suisse","authors":["Golshayan, Dela","Aubert, John-David","Hullin, Roger","Moradpour, Darius","Venetz, Jean-Pierre","Manuel, Oriol","Pascual, Manuel"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348042","source":"PubMed","week":"202018|Apr 27 - May 03","topics":["Treatment","Prevention"],"weight":1,"_version_":1666138494950440961,"score":388.2944},{"pmid":32389803,"title":"Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia.","text":["Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia.","The COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplant conditioning. The effect on transplant outcomes in non-malignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the US during 2013-2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received non-cryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (HR 2.26, 95% CI 1.17 - 4.35, p=0.01) and of 1-year overall mortality (HR 3.13, 95% CI 1.60 - 6.11, p=0.0008) after transplantation of cryopreserved compared to non-cryopreserved grafts with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match). Acute and chronic GVHD did not differ between groups. Adjusted probabilities of 1-year survival were 73% (95% 60 - 84) and 91% (95% CI 86 - 94) with cryopreserved and non-cryopreserved grafts, respectively. These data support the use of non-cryopreserved grafts, when possible, for severe aplastic anemia.","Biol Blood Marrow Transplant","Eapen, Mary","Zhang, Mei-Jie","Tang, Xiao-Ying","Lee, Stephanie J","Fei, Ming-Wei","Wang, Hai-Lin","Hebert, Kyle M","Arora, Mukta","Chhabra, Saurabh","Devine, Steven M","Hamadani, Mehdi","D'Souza, Anita","Pasquini, Marcelo C","Phelan, Rachel","Rizzo, J Douglas","Saber, Wael","Shaw, Bronwen E","Weisdorf, Daniel J","Horowitz, Mary M","32389803"],"abstract":["The COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplant conditioning. The effect on transplant outcomes in non-malignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the US during 2013-2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received non-cryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (HR 2.26, 95% CI 1.17 - 4.35, p=0.01) and of 1-year overall mortality (HR 3.13, 95% CI 1.60 - 6.11, p=0.0008) after transplantation of cryopreserved compared to non-cryopreserved grafts with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match). Acute and chronic GVHD did not differ between groups. Adjusted probabilities of 1-year survival were 73% (95% 60 - 84) and 91% (95% CI 86 - 94) with cryopreserved and non-cryopreserved grafts, respectively. These data support the use of non-cryopreserved grafts, when possible, for severe aplastic anemia."],"journal":"Biol Blood Marrow Transplant","authors":["Eapen, Mary","Zhang, Mei-Jie","Tang, Xiao-Ying","Lee, Stephanie J","Fei, Ming-Wei","Wang, Hai-Lin","Hebert, Kyle M","Arora, Mukta","Chhabra, Saurabh","Devine, Steven M","Hamadani, Mehdi","D'Souza, Anita","Pasquini, Marcelo C","Phelan, Rachel","Rizzo, J Douglas","Saber, Wael","Shaw, Bronwen E","Weisdorf, Daniel J","Horowitz, Mary M"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389803","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.bbmt.2020.04.027","keywords":["cryopreserved graft","severe aplastic anemia"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666528580263215104,"score":358.47684},{"pmid":32476285,"title":"Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.","text":["Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.","Universal screening of potential organ donors and recipients for SARS-CoV-2 is now recommended prior to transplantation in the United States during the COVID-19 pandemic. Challenges have included limited testing capacity, short windows of organ viability, brief lead time for notification of potential organ recipients, and the need to test lower respiratory donor specimens to optimize sensitivity. In an early US epicenter of the outbreak, we designed and implemented a system to expedite this testing and here report results from the first three weeks. The process included a Laboratory Medicine designee for communication with organ recovery and transplant clinical staff, specialized sample labeling and handoff, and priority processing. Thirty-two organs recovered from 14 of 17 screened donors were transplanted versus 70 recovered from 23 donors during the same period in 2019. No pre-transplant or organ donors tested positive for SARS-CoV-2. Median turnaround time from specimen receipt was 6.8h (donors), 6.5h (recipients): 4.5h faster than daily inpatient median. No organ recoveries or transplants were disrupted by a lack of SARS-CoV-2 testing. Waitlist inactivations for COVID-19 precautions were reduced in our region. Systems that include specialized ordering pathways and adequate testing capacity can support continued organ transplantation even in a SARS-CoV-2 hyperendemic area.","Am J Transplant","Lieberman, Joshua A","Mays, James A","Wells, Candy","Cent, Anne","Bell, Deborah","Bankson, Daniel D","Greninger, Alex L","Jerome, Keith R","Limaye, Ajit P","32476285"],"abstract":["Universal screening of potential organ donors and recipients for SARS-CoV-2 is now recommended prior to transplantation in the United States during the COVID-19 pandemic. Challenges have included limited testing capacity, short windows of organ viability, brief lead time for notification of potential organ recipients, and the need to test lower respiratory donor specimens to optimize sensitivity. In an early US epicenter of the outbreak, we designed and implemented a system to expedite this testing and here report results from the first three weeks. The process included a Laboratory Medicine designee for communication with organ recovery and transplant clinical staff, specialized sample labeling and handoff, and priority processing. Thirty-two organs recovered from 14 of 17 screened donors were transplanted versus 70 recovered from 23 donors during the same period in 2019. No pre-transplant or organ donors tested positive for SARS-CoV-2. Median turnaround time from specimen receipt was 6.8h (donors), 6.5h (recipients): 4.5h faster than daily inpatient median. No organ recoveries or transplants were disrupted by a lack of SARS-CoV-2 testing. Waitlist inactivations for COVID-19 precautions were reduced in our region. Systems that include specialized ordering pathways and adequate testing capacity can support continued organ transplantation even in a SARS-CoV-2 hyperendemic area."],"journal":"Am J Transplant","authors":["Lieberman, Joshua A","Mays, James A","Wells, Candy","Cent, Anne","Bell, Deborah","Bankson, Daniel D","Greninger, Alex L","Jerome, Keith R","Limaye, Ajit P"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476285","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16081","keywords":["covid-19","organ transplant","sars-cov-2","rapid testing","turnaround time"],"locations":["United States","US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1668532089457213440,"score":357.9238},{"pmid":32202064,"title":"COVID-19: A global transplant perspective on successfully navigating a pandemic.","text":["COVID-19: A global transplant perspective on successfully navigating a pandemic.","The COVID-19 pandemic has rapidly evolved and changed our way of life in an unprecedented manner. The emergence of COVID-19 has impacted transplantation worldwide. The impact has not been just restricted to issues pertaining to donors or recipients, but also health-care resource utilization as the intensity of cases in certain jurisdictions exceeds available capacity. Here we provide a personal viewpoint representing different jurisdictions from around the world in order to outline the impact of the current COVID-19 pandemic on organ transplantation. Based on our collective experience, we discuss mitigation strategies such as donor screening, resource planning, and a staged approach to transplant volume considerations as local resource issues demand. We also discuss issues related to transplant-related research during the pandemic, the role of transplant infectious diseases, and the influence of transplant societies for education and disseminating current information.","Am J Transplant","Kumar, Deepali","Manuel, Oriol","Natori, Yoichiro","Egawa, Hiroto","Grossi, Paolo","Han, Sang-Hoon","Fernandez-Ruiz, Mario","Humar, Atul","32202064"],"abstract":["The COVID-19 pandemic has rapidly evolved and changed our way of life in an unprecedented manner. The emergence of COVID-19 has impacted transplantation worldwide. The impact has not been just restricted to issues pertaining to donors or recipients, but also health-care resource utilization as the intensity of cases in certain jurisdictions exceeds available capacity. Here we provide a personal viewpoint representing different jurisdictions from around the world in order to outline the impact of the current COVID-19 pandemic on organ transplantation. Based on our collective experience, we discuss mitigation strategies such as donor screening, resource planning, and a staged approach to transplant volume considerations as local resource issues demand. We also discuss issues related to transplant-related research during the pandemic, the role of transplant infectious diseases, and the influence of transplant societies for education and disseminating current information."],"journal":"Am J Transplant","authors":["Kumar, Deepali","Manuel, Oriol","Natori, Yoichiro","Egawa, Hiroto","Grossi, Paolo","Han, Sang-Hoon","Fernandez-Ruiz, Mario","Humar, Atul"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202064","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1111/ajt.15876","keywords":["clinical decision-making","clinical research/practice","donors and donation: donor-derived infections","infection and infectious agents - viral","infectious disease","organ transplantation in general"],"topics":["Treatment"],"weight":1,"_version_":1666138492416032768,"score":341.24078},{"pmid":32476233,"title":"Strategies for Liver Transplantation during the SARS CoV-2 Outbreak Preliminary Experience from a Single Center in France.","text":["Strategies for Liver Transplantation during the SARS CoV-2 Outbreak Preliminary Experience from a Single Center in France.","Liver transplantation during the ongoing SARS-CoV-2 pandemic is challenging given the urgent need to reallocate resources to other areas of patient care. Available guidelines recommend to reorganize transplant care but data on clinical experience in the context of SARS-CoV-2 pandemic are scarce. Thus, we report strategies and preliminary results in liver transplantation during the peak of the SARS-CoV-2 pandemic from a single-center in France. Our strategy to reorganize the transplant program included four main steps: optimization of available resources especially intensive care unit capacity, multidisciplinary risk stratification of liver transplantation candidates on the waiting list, implementation of a systematic SARS-CoV-2 screening strategy prior to transplantation and definition of optimal recipient-donor matching. After implementation of these four steps, we performed 10 successful liver transplantations during the peak of the pandemic with a short median intensive care unit stay (2,5 days), benchmark post-transplant morbidity and no occurrence of SARS-CoV-2 infection during follow-up. From this preliminary experience we conclude that efforts in resource planning, optimal recipient selection and organ allocation strategy are key to maintain a safe liver transplant activity. Transplant centers should be ready to readapt their practices as the pandemic evolves.","Am J Transplant","Muller, Xavier","Tilmans, Gilles","Chenevas-Paule, Quentin","Lebosse, Fanny","Antonini, Teresa","Poinsot, Domitille","Rode, Agnes","Guichon, Celine M","Schmitt, Zoe","Ducerf, Christian","Mohkam, Kayvan","Lesurtel, Mickael","Mabrut, Jean-Yves","32476233"],"abstract":["Liver transplantation during the ongoing SARS-CoV-2 pandemic is challenging given the urgent need to reallocate resources to other areas of patient care. Available guidelines recommend to reorganize transplant care but data on clinical experience in the context of SARS-CoV-2 pandemic are scarce. Thus, we report strategies and preliminary results in liver transplantation during the peak of the SARS-CoV-2 pandemic from a single-center in France. Our strategy to reorganize the transplant program included four main steps: optimization of available resources especially intensive care unit capacity, multidisciplinary risk stratification of liver transplantation candidates on the waiting list, implementation of a systematic SARS-CoV-2 screening strategy prior to transplantation and definition of optimal recipient-donor matching. After implementation of these four steps, we performed 10 successful liver transplantations during the peak of the pandemic with a short median intensive care unit stay (2,5 days), benchmark post-transplant morbidity and no occurrence of SARS-CoV-2 infection during follow-up. From this preliminary experience we conclude that efforts in resource planning, optimal recipient selection and organ allocation strategy are key to maintain a safe liver transplant activity. Transplant centers should be ready to readapt their practices as the pandemic evolves."],"journal":"Am J Transplant","authors":["Muller, Xavier","Tilmans, Gilles","Chenevas-Paule, Quentin","Lebosse, Fanny","Antonini, Teresa","Poinsot, Domitille","Rode, Agnes","Guichon, Celine M","Schmitt, Zoe","Ducerf, Christian","Mohkam, Kayvan","Lesurtel, Mickael","Mabrut, Jean-Yves"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476233","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16082","locations":["France","optimal","optimal","France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1668437834987470848,"score":336.30115}]}